These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36191532)

  • 1. Risks and overdose responses: Participant characteristics from the first seven years of a national take-home naloxone program.
    Ericson ØB; Eide D; Lobmaier P; Clausen T
    Drug Alcohol Depend; 2022 Nov; 240():109645. PubMed ID: 36191532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sweden's first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals.
    Holmén E; Warnqvist A; Kåberg M
    Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):24. PubMed ID: 37087485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who is using take-home naloxone? An examination of supersavers.
    Eide D; Lobmaier P; Clausen T
    Harm Reduct J; 2022 Jun; 19(1):65. PubMed ID: 35717240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.
    Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E
    Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use.
    Curtis M; Dietze P; Aitken C; Kirwan A; Kinner SA; Butler T; Stoové M
    Harm Reduct J; 2018 Sep; 15(1):48. PubMed ID: 30241532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.
    Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injection Drug Use Frequency Before and After Take-Home Naloxone Training.
    Colledge-Frisby S; Rathnayake K; Nielsen S; Stoove M; Maher L; Agius PA; Higgs P; Dietze P
    JAMA Netw Open; 2023 Aug; 6(8):e2327319. PubMed ID: 37540514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of and Experience Among People Who Use Take-Home Naloxone in Skåne County, Sweden.
    Troberg K; Isendahl P; Blomé MA; Dahlman D; Håkansson A
    Front Public Health; 2022; 10():811001. PubMed ID: 35359781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
    Moustaqim-Barrette A; Papamihali K; Mamdani Z; Williams S; Buxton JA
    PLoS One; 2020; 15(9):e0238618. PubMed ID: 32915834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
    O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
    BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program.
    Rowe C; Santos GM; Vittinghoff E; Wheeler E; Davidson P; Coffin PO
    Addiction; 2015 Aug; 110(8):1301-10. PubMed ID: 25917125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
    Holmén E; Hammarberg A; Kåberg M; Storbjörk J
    Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids.
    Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L
    Pain Med; 2018 Mar; 19(3):533-540. PubMed ID: 28340185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid education and nasal naloxone rescue kits in the emergency department.
    Dwyer K; Walley AY; Langlois BK; Mitchell PM; Nelson KP; Cromwell J; Bernstein E
    West J Emerg Med; 2015 May; 16(3):381-4. PubMed ID: 25987910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
    Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
    Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.